MCID: SRC014
MIFTS: 70

Sarcoma

Categories: Bone diseases, Cancer diseases

Aliases & Classifications for Sarcoma

MalaCards integrated aliases for Sarcoma:

Name: Sarcoma 12 29 55 6 15 73
Connective and Soft Tissue Neoplasm 12
Tumor of Soft Tissue and Skeleton 12
Sarcoma - Category 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1115
ICD10 33 C49
ICD9CM 35 171 171.9
SNOMED-CT 68 93765001

Summaries for Sarcoma

Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from embryonic mesoderm.

MalaCards based summary : Sarcoma, also known as connective and soft tissue neoplasm, is related to ewing sarcoma and sarcoma, synovial. An important gene associated with Sarcoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are GPCR Pathway and TGF-Beta Pathway. The drugs Doxil and Fusilev have been mentioned in the context of this disorder. Affiliated tissues include bone, myeloid and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 A sarcoma is a cancer that arises from transformed cells of mesenchymal (Connective Tissue) origin.... more...

Related Diseases for Sarcoma

Diseases related to Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1215)
# Related Disease Score Top Affiliating Genes
1 ewing sarcoma 34.4 TP53 RB1 KIT JUN FLI1 EWSR1
2 sarcoma, synovial 34.3 KIT SSX1 SSX2
3 undifferentiated pleomorphic sarcoma 34.1 PIK3CA KRAS KIT
4 osteogenic sarcoma 34.0 TP53 RB1 HOTAIR CHEK2
5 gastrointestinal stromal tumor 33.1 TP53 KRAS KIT HOTAIR BRAF
6 uterine carcinosarcoma 33.0 TP53 PIK3CA KIT HRAS
7 li-fraumeni syndrome 2 32.6 CHEK2 TP53
8 muscle cancer 32.5 TP53 KIT EWSR1
9 malignant mesenchymoma 32.3 TP53 KIT EWSR1
10 carcinosarcoma 32.3 TP53 PIK3CA KRAS KIT HRAS
11 breast cancer 32.2 TP53 SRC RB1 PIK3CA KRAS KIT
12 liver angiosarcoma 31.8 TP53 KRAS HRAS
13 ewing's family of tumors 31.4 RB1 KIT FLI1 EWSR1
14 histiocytoma 31.0 EWSR1 KIT TP53
15 leukemia, acute myeloid 30.9 TP53 KRAS KIT JUN HRAS HOTAIR
16 adenocarcinoma 30.8 TP53 RB1 PIK3CA KRAS KIT HRAS
17 angiosarcoma 30.8 FLI1 KIT KRAS
18 myelodysplastic syndrome 30.7 CHEK2 HRAS KIT KRAS TP53
19 leukemia, chronic lymphocytic 2 30.5 TP53 KRAS HRAS BRAF
20 leukemia, chronic lymphocytic 30.4 TP53 LYN KRAS HRAS BRAF
21 neuroblastoma 30.4 HOTAIR KIT LYN PIK3CA TP53
22 cystadenocarcinoma 30.3 HRAS PIK3CA TP53
23 squamous cell carcinoma 30.3 TP53 RB1 PIK3CA HRAS HOTAIR CHEK2
24 leukemia, chronic myeloid 30.2 SRC LYN KIT HRAS HOTAIR FES
25 myeloma, multiple 30.2 TP53 KRAS KIT HRAS HOTAIR BRAF
26 glioblastoma 30.1 TP53 SRC RB1 PIK3CA HRAS HOTAIR
27 lung cancer 30.0 TP53 RB1 PIK3CA KRAS KIT JUN
28 small cell cancer of the lung 30.0 TP53 RB1 PIK3CA KIT HOTAIR
29 testicular germ cell tumor 30.0 TP53 KIT HRAS BRAF
30 ovarian cancer 29.9 TP53 PIK3CA KRAS JUN HOTAIR CHEK2
31 thymoma, familial 29.9 HRAS KIT
32 pulmonic stenosis 29.9 KRAS HRAS BRAF
33 cervical cancer 29.9 HOTAIR HRAS PIK3CA RB1 TP53
34 lung cancer susceptibility 3 29.9 TP53 SRC PIK3CA KRAS JUN HRAS
35 adenoid cystic carcinoma 29.9 TP53 PIK3CA KRAS KIT HRAS CHEK2
36 thyroid cancer 29.9 TP53 PIK3CA KRAS KIT HRAS HOTAIR
37 colorectal cancer 29.9 BRAF CHEK2 HOTAIR HRAS JUN KRAS
38 bladder cancer 29.8 TP53 SRC RB1 KRAS HRAS HOTAIR
39 nasopharyngeal carcinoma 29.8 TP53 PIK3CA JUN HRAS HOTAIR
40 prostate cancer 29.8 TP53 SRC RB1 PIK3CA KRAS JUN
41 connective tissue cancer 29.8 TP53 SSX1 KIT EWSR1
42 spitz nevus 29.8 TP53 HRAS BRAF
43 mature teratoma 29.8 TP53 KRAS BRAF
44 lung adenoid cystic carcinoma 29.7 PIK3CA KRAS KIT HRAS
45 ovary adenocarcinoma 29.7 TP53 PIK3CA KRAS HRAS
46 intestinal disease 29.7 TP53 PIK3CA KRAS HRAS
47 pancreas adenocarcinoma 29.7 TP53 SRC PIK3CA KRAS HRAS
48 ovarian cancer 1 29.7 KRAS PIK3CA TP53
49 adrenocortical carcinoma, hereditary 29.7 TP53 PIK3CA CHEK2 BRAF
50 rectal neoplasm 29.7 HRAS KRAS TP53

Graphical network of the top 20 diseases related to Sarcoma:



Diseases related to Sarcoma

Symptoms & Phenotypes for Sarcoma

GenomeRNAi Phenotypes related to Sarcoma according to GeneCards Suite gene sharing:

26 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.97 BRAF KRAS HRAS PIK3CA
2 Decreased viability GR00106-A-0 10.97 KRAS
3 Decreased viability GR00221-A-1 10.97 KIT KRAS HRAS PIK3CA
4 Decreased viability GR00221-A-2 10.97 KRAS HRAS PIK3CA CHEK2 JUN YES1
5 Decreased viability GR00221-A-3 10.97 HRAS CHEK2 JUN LYN YES1
6 Decreased viability GR00221-A-4 10.97 BRAF PIK3CA CHEK2 YES1
7 Decreased viability GR00301-A 10.97 BRAF KIT KRAS SRC
8 Decreased viability GR00342-S-1 10.97 LYN
9 Decreased viability GR00342-S-2 10.97 CHEK2 LYN
10 Decreased viability GR00342-S-3 10.97 LYN
11 Decreased viability GR00381-A-1 10.97 BRAF KRAS
12 Decreased viability GR00402-S-2 10.97 BRAF KIT KRAS SRC HRAS PIK3CA
13 Decreased substrate adherent cell growth GR00193-A-1 10.1 KIT
14 Decreased substrate adherent cell growth GR00193-A-2 10.1 KIT YES1
15 Decreased substrate adherent cell growth GR00193-A-3 10.1 BRAF CHEK2 YES1
16 Decreased substrate adherent cell growth GR00193-A-4 10.1 BRAF CHEK2 KIT YES1
17 Decreased cell migration GR00055-A-1 9.98 BRAF FES HRAS KRAS LYN PIK3CA
18 Decreased viability in esophageal squamous lineage GR00235-A 9.96 BRAF CHEK2 HRAS JUN KIT KRAS
19 Decreased telomerase activity GR00156-A 9.67 CHEK2 FES SRC YES1
20 Increased cell migration GR00055-A-3 9.35 BRAF HRAS KRAS LYN PIK3CA
21 Decreased viability in HMC1.1 cells GR00105-A-0 9.33 KIT LYN SRC
22 Increased cell viability after pRB stimulation GR00230-A-1 8.92 CHEK2 FES KIT YES1

MGI Mouse Phenotypes related to Sarcoma:

46 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.35 BRAF CHEK2 FES FLI1 HRAS JUN
2 growth/size/body region MP:0005378 10.35 BRAF FES FLI1 HRAS JUN KIT
3 immune system MP:0005387 10.35 BRAF CHEK2 FES FLI1 JUN KIT
4 hematopoietic system MP:0005397 10.34 BRAF CHEK2 FES FLI1 JUN KIT
5 mortality/aging MP:0010768 10.34 BRAF CHEK2 FES FLI1 HRAS JUN
6 homeostasis/metabolism MP:0005376 10.33 BRAF CHEK2 FES HRAS JUN KIT
7 cardiovascular system MP:0005385 10.3 BRAF FES FLI1 HRAS JUN KIT
8 integument MP:0010771 10.3 BRAF FES HRAS JUN KIT KRAS
9 nervous system MP:0003631 10.28 BRAF CHEK2 FES FLI1 HRAS JUN
10 embryo MP:0005380 10.24 BRAF FLI1 JUN KIT KRAS PIK3CA
11 craniofacial MP:0005382 10.2 BRAF FES HRAS KIT KRAS RB1
12 neoplasm MP:0002006 10.2 BRAF CHEK2 FES FLI1 HRAS KIT
13 digestive/alimentary MP:0005381 10.19 BRAF FES HRAS KIT KRAS LYN
14 liver/biliary system MP:0005370 10.16 BRAF FES FLI1 JUN KIT KRAS
15 muscle MP:0005369 10.08 BRAF FES FLI1 KIT KRAS PIK3CA
16 normal MP:0002873 10.02 BRAF FES HRAS JUN KIT KRAS
17 no phenotypic analysis MP:0003012 9.95 HRAS JUN KIT KRAS PIK3CA RB1
18 renal/urinary system MP:0005367 9.86 BRAF HRAS KIT KRAS LYN RB1
19 respiratory system MP:0005388 9.85 BRAF HRAS JUN KIT KRAS LYN
20 pigmentation MP:0001186 9.8 BRAF KIT KRAS RB1 SRC TP53
21 skeleton MP:0005390 9.65 BRAF HRAS JUN KIT KRAS PIK3CA
22 vision/eye MP:0005391 9.28 BRAF FES JUN KIT KRAS PIK3CA

Drugs & Therapeutics for Sarcoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Doxil 18 49 DOXORUBICIN HYDROCHLORIDE Alza June 1999
2
Fusilev 18 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
3
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
4
Taxol 18 49 PACLITAXEL Bristol-Myers Squibb August 1997
5
Votrient 18 49 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009

Drugs for Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 647)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
3
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-22-7, 2068-78-2 5978
4
Bleomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
5
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 155213-67-5 392622
6
Efavirenz Approved, Investigational Phase 4,Phase 3,Not Applicable 154598-52-4 64139
7
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
8
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
9
Mechlorethamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
10
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3778-73-2 3690
11
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 134678-17-4 60825
12
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
13
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
14
Emtricitabine Approved, Investigational Phase 4,Phase 3,Not Applicable 143491-57-0 60877
15
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
16
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
17
Aprepitant Approved, Investigational Phase 4,Phase 2,Not Applicable 170729-80-3 6918365 151165
18
Fosaprepitant Approved Phase 4,Phase 2,Not Applicable 172673-20-0 219090
19
Lithium carbonate Approved Phase 4,Not Applicable 554-13-2
20
Enoxaparin Approved Phase 4,Not Applicable 9005-49-6 772
21
Heparin Approved, Investigational Phase 4,Phase 1,Not Applicable 9005-49-6 772 46507594
22
Aspirin Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-78-2 2244
23
Dalteparin Approved Phase 4,Phase 1,Not Applicable 9005-49-6
24
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
25
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
26
Tenofovir Experimental, Investigational Phase 4,Phase 3,Not Applicable 147127-20-6 464205
27
Substance P Investigational Phase 4,Phase 2,Not Applicable 33507-63-0 44359816
28 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Vaccines Phase 4,Phase 3,Phase 1,Phase 2
37 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
38 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
40 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
41 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Cola Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
46 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
47 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
49
Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 0
50 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1892)
# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
3 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
4 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
5 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
6 OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. Completed NCT00577031 Phase 4 bevacizumab [Avastin];Oxaliplatin;Xeloda
7 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
8 Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Recruiting NCT03144206 Phase 4 Hyperbaric oxygen
9 Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma Recruiting NCT03514381 Phase 4 Patients starting a treatment with Doxorubicin and Ifosfamide
10 Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib Recruiting NCT03735758 Phase 4 Pazopanib or chemotherapy
11 Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4 Panitumumab
12 Effects of a Neuroscience-based Technique on Post-traumatic Stress Disorder Symptoms, Inflammation, and Survival in Cancer Patients Announced of a Palliative Disease Progression and Their Partners Recruiting NCT03652298 Phase 4
13 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
14 Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Recruiting NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
15 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
16 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
17 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
18 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Unknown status NCT01344018 Phase 3
19 Role of Barrier Resection in Local Control for Extremity Recurrent Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
20 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
21 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
22 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
23 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
24 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma Unknown status NCT00354744 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
25 I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations Unknown status NCT02818725 Phase 3 Chemotherapy;panitumumab
26 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
27 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
28 Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor Unknown status NCT00685828 Phase 3 imatinib mesylate
29 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3 Docetaxel+lobaplatin;Gemcitabine+lobaplatin
30 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3 Zoledronic acid;Standard chemotherapy
31 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Unknown status NCT00075582 Phase 3 dactinomycin;cyclophosphamide;vincristine sulfate
32 A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Completed NCT01440088 Phase 3 TH-302 in Combination with Doxorubicin;Doxorubicin
33 A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma Completed NCT00131898 Phase 3
34 Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma Completed NCT00142571 Phase 3 Gemcitabine;Docetaxel
35 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
36 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
37 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
38 Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Completed NCT02049905 Phase 3 Aldoxorubicin;Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
39 Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma Completed NCT01327885 Phase 3 Eribulin mesylate 1.4 mg/m^2 intravenous;Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
40 An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) Completed NCT00796120 Phase 3 Trabectedin;Doxorubicin;Ifosfamide
41 Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma Completed NCT02672527 Phase 3 Trabectedin;Dexamethasone
42 Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma Completed NCT01168791 Phase 3 doxorubicin in combination with palifosfamide-tris;doxorubicin in combination with placebo
43 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
44 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
45 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
46 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
47 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir
48 Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride
49 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Completed NCT00538239 Phase 3 ridaforolimus;Placebo
50 A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)

Search NIH Clinical Center for Sarcoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Sarcoma

Genetic tests related to Sarcoma:

# Genetic test Affiliating Genes
1 Sarcoma 29

Anatomical Context for Sarcoma

MalaCards organs/tissues related to Sarcoma:

41
Bone, Myeloid, Lung, Liver, Kidney, T Cells, Uterus

Publications for Sarcoma

Articles related to Sarcoma:

(show top 50) (show all 15897)
# Title Authors Year
1
Impact of cyclophosphamide and etoposide on outcome of clear cell sarcoma of the kidney treated on the National Wilms Tumor Study-5 (NWTS-5). ( 30255545 )
2019
2
Early recognition and diagnosis of Ewing sarcoma of the cervical spine. ( 30416636 )
2019
3
Clinicopathologic Features of Non-CNS Primary Ewing Sarcoma Family of Tumors in the Head and Neck Region. Don't Forget the CIC- and BCOR-rearranged Sarcomas. ( 28777154 )
2019
4
Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma. ( 30270506 )
2019
5
KSHV viral load and Interleukin-6 in HIV-associated pediatric Kaposi sarcoma-Exploring the role of lytic activation in driving the unique clinical features seen in endemic regions. ( 30204240 )
2019
6
Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Associated Disease in the AIDS Patient: An Update. ( 30523621 )
2019
7
Cardiotoxicity with trabectedin in the treatment of advanced soft tissue sarcoma. ( 30540596 )
2019
8
A rare case of nasal biphenotypic sino-nasal sarcoma in a young female. ( 30555691 )
2019
9
Re‑irradiation plus hyperthermia for recurrent pediatric sarcoma; a simulation study to investigate feasibility. ( 30387837 )
2019
10
Localized synovial sarcoma of the foot or ankle: A series of 32 Cooperative Weichteilsarkom Study Group patients. ( 30421433 )
2019
11
Synovial sarcoma of bone: Sarcoma typically of soft tissues presenting as a primary bone tumor. ( 30425775 )
2019
12
miR‑494.3p expression in synovial sarcoma: Role of CXCR4 as a potential target gene. ( 30431073 )
2019
13
Outcomes of Elderly Patients Undergoing Curative Resection for Retroperitoneal Sarcomas: Analysis From the US Sarcoma Collaborative. ( 30502242 )
2019
14
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. ( 29553955 )
2018
15
EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma. ( 29945296 )
2018
16
Surgical management of esophageal sarcoma: a multicenter European experience. ( 29444281 )
2018
17
Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma. ( 29472043 )
2018
18
Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets. ( 29416716 )
2018
19
Kaposi Sarcoma in the Era of Rapamycin Remains a Therapeutic Challenge in Organ Transplant Recipients. ( 29527986 )
2018
20
Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases. ( 29225052 )
2018
21
Can the risks associated with uterine sarcoma morcellation really be prevented? Overview of the role of uterine morcellation in 2018. ( 29879489 )
2018
22
Characterizing the potency and impact of carbon ion therapy in a primary mouse model of soft tissue sarcoma. ( 29437879 )
2018
23
The Role of Adjuvant Radiotherapy for a Case of Primary Breast Sarcoma: A Plan Comparison between Three Modern Techniques and a Review of the Literature. ( 29849658 )
2018
24
RTK-RAS pathway mutation is enriched in myeloid sarcoma. ( 29789584 )
2018
25
Primary mediastinal histiocytic sarcoma presenting as pleural effusion. ( 29756323 )
2018
26
Fine needle aspiration of alveolar soft part sarcoma in a child: Cytomorphological clues for the surgical pathologist. ( 29661735 )
2018
27
A Rare Case of Retroperitoneal Follicular Dendritic Cell Sarcoma Identified by 99mTc-HYNIC-TOC SPECT/CT. ( 29863574 )
2018
28
Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients. ( 29384032 )
2018
29
Hepatic endometrial stromal sarcoma. ( 29843927 )
2018
30
Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. ( 29308306 )
2018
31
The t(1;10)(p22;q24) TGFBR3/MGEA5 Translocation in Pleomorphic Hyalinizing Angiectatic Tumor (PHAT), Myxoinflammatory Fibroblastic Sarcoma (MIFS), and Hemosiderotic Fibrolipomatous Tumor (HFLT). ( 29979612 )
2018
32
Evolution of Kaposi sarcoma in the past 30A years in a tertiary hospital of the European Mediterranean basin. ( 29934954 )
2018
33
Planning for Bone Excision in Ewing Sarcoma: Post-Chemotherapy MRI More Accurate Than Pre-Chemotherapy MRI Assessment. ( 29298256 )
2018
34
MicroRNA-638 inhibits cell growth and tubule formation by suppressing VEGFA expression in human Ewing sarcoma cells. ( 29263143 )
2018
35
Hanging Undifferentiated Embryonal Sarcoma of the Liver in Adult: an Unusual Presentation of an Aggressive Tumor. ( 29779073 )
2018
36
RIG-I Detects Kaposi's Sarcoma-Associated Herpesvirus Transcripts in a RNA Polymerase III-Independent Manner. ( 29970461 )
2018
37
Mediastinal monophasic synovial sarcoma with pericardial extension causing hemodynamic instability. ( 29765618 )
2018
38
Simultaneous Brain and Lung Histiocytic Sarcoma Revealed on 18F-FDG PET/CT. ( 29189378 )
2018
39
Case of classic Kaposi sarcoma of the penis successfully treated with radiotherapy. ( 29341256 )
2018
40
Coexistent cutaneous myeloid sarcoma in a patient with invasive papillary carcinoma of thyroid - A rare presentation. ( 29855456 )
2018
41
Intramuscular Epithelioid Sarcoma Presenting as Extrinsic Flexor Tightness inA the Forearm. ( 29602652 )
2018
42
A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report. ( 29357824 )
2018
43
Treatment of Uterine Sarcoma with rAd-p53 (Gendicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy. ( 29281902 )
2018
44
SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma. ( 29700418 )
2018
45
CORR InsightsAr: Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma? ( 29443851 )
2018
46
Establishment and proteomic characterization of a novel cell line, NCC-UPS2-C1, derived from a patient with undifferentiated pleomorphic sarcoma. ( 29359268 )
2018
47
Alveolar Soft Part Sarcoma Presenting as Hypervascular Adrenal Metastasis. ( 29398970 )
2018
48
Paraneoplastic Pemphigus as a First Manifestation of an Intra-Abdominal Follicular Dendritic Cell Sarcoma: Rare Case and Review of the Literature. ( 29928216 )
2018
49
Primary jejunal interdigitating dendritic cell sarcoma. ( 29414390 )
2018
50
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients With Refractory Metastatic Soft Tissue Sarcoma. ( 29895706 )
2018

Variations for Sarcoma

ClinVar genetic disease variations for Sarcoma:

6 (show all 30)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
2 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
3 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
4 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
5 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
6 FGFR3 NM_000142.4(FGFR3): c.1887C> T (p.Asn629=) single nucleotide variant not provided rs104886004 GRCh37 Chromosome 4, 1807828: 1807828
7 FGFR3 NM_000142.4(FGFR3): c.1887C> T (p.Asn629=) single nucleotide variant not provided rs104886004 GRCh38 Chromosome 4, 1806101: 1806101
8 FGFR3 NM_000142.4(FGFR3): c.1908C> G (p.Phe636Leu) single nucleotide variant not provided rs104886005 GRCh37 Chromosome 4, 1807849: 1807849
9 FGFR3 NM_000142.4(FGFR3): c.1908C> G (p.Phe636Leu) single nucleotide variant not provided rs104886005 GRCh38 Chromosome 4, 1806122: 1806122
10 FGFR3 NM_000142.4(FGFR3): c.1935C> T (p.Leu645=) single nucleotide variant not provided rs104886006 GRCh37 Chromosome 4, 1807876: 1807876
11 FGFR3 NM_000142.4(FGFR3): c.1935C> T (p.Leu645=) single nucleotide variant not provided rs104886006 GRCh38 Chromosome 4, 1806149: 1806149
12 PIK3CA NM_006218.2: c.1821+51A> T single nucleotide variant not provided
13 FGFR3 NM_022965.3(FGFR3): c.1799G> A (p.Arg600His) single nucleotide variant not provided rs104886024 GRCh37 Chromosome 4, 1808377: 1808377
14 FGFR3 NM_022965.3(FGFR3): c.1799G> A (p.Arg600His) single nucleotide variant not provided rs104886024 GRCh38 Chromosome 4, 1806650: 1806650
15 KRAS NM_033360.3(KRAS): c.216G> A (p.Met72Ile) single nucleotide variant not provided rs104886028 GRCh37 Chromosome 12, 25380242: 25380242
16 KRAS NM_033360.3(KRAS): c.216G> A (p.Met72Ile) single nucleotide variant not provided rs104886028 GRCh38 Chromosome 12, 25227308: 25227308
17 KRAS NM_033360.3(KRAS): c.219G> A (p.Arg73=) single nucleotide variant not provided rs104886027 GRCh37 Chromosome 12, 25380239: 25380239
18 KRAS NM_033360.3(KRAS): c.219G> A (p.Arg73=) single nucleotide variant not provided rs104886027 GRCh38 Chromosome 12, 25227305: 25227305
19 TP53 NM_000546.5(TP53): c.886C> T (p.His296Tyr) single nucleotide variant Uncertain significance rs672601296 GRCh37 Chromosome 17, 7577052: 7577052
20 TP53 NM_000546.5(TP53): c.886C> T (p.His296Tyr) single nucleotide variant Uncertain significance rs672601296 GRCh38 Chromosome 17, 7673734: 7673734
21 TP53 NM_000546.5(TP53): c.969G> A (p.Leu323=) single nucleotide variant Likely benign rs672601297 GRCh37 Chromosome 17, 7576877: 7576877
22 TP53 NM_000546.5(TP53): c.969G> A (p.Leu323=) single nucleotide variant Likely benign rs672601297 GRCh38 Chromosome 17, 7673559: 7673559
23 TP53 NM_000546.5(TP53): c.448_459delACACCCCCGCCC (p.Thr150_Pro153del) deletion not provided rs137852790 GRCh37 Chromosome 17, 7578471: 7578482
24 TP53 NM_000546.5(TP53): c.448_459delACACCCCCGCCC (p.Thr150_Pro153del) deletion not provided rs137852790 GRCh38 Chromosome 17, 7675153: 7675164
25 TP53 NM_000546.5(TP53): c.450_459delACCCCCGCCC (p.Pro151Alafs) deletion not provided rs137852791 GRCh37 Chromosome 17, 7578471: 7578480
26 TP53 NM_000546.5(TP53): c.450_459delACCCCCGCCC (p.Pro151Alafs) deletion not provided rs137852791 GRCh38 Chromosome 17, 7675153: 7675162
27 TP53 NM_000546.5(TP53): c.460G> A (p.Gly154Ser) single nucleotide variant Uncertain significance rs137852789 GRCh37 Chromosome 17, 7578470: 7578470
28 TP53 NM_000546.5(TP53): c.460G> A (p.Gly154Ser) single nucleotide variant Uncertain significance rs137852789 GRCh38 Chromosome 17, 7675152: 7675152
29 CHEK2 NM_007194.4(CHEK2): c.341G> A (p.Trp114Ter) single nucleotide variant Pathogenic GRCh37 Chromosome 22, 29121334: 29121334
30 CHEK2 NM_007194.4(CHEK2): c.341G> A (p.Trp114Ter) single nucleotide variant Pathogenic GRCh38 Chromosome 22, 28725346: 28725346

Expression for Sarcoma

Search GEO for disease gene expression data for Sarcoma.

Pathways for Sarcoma

Pathways related to Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 174)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 BRAF HRAS JUN KIT KRAS LYN
2
Show member pathways
13.66 BRAF HRAS JUN KIT KRAS PIK3CA
3
Show member pathways
13.63 BRAF FES HRAS JUN KIT KRAS
4
Show member pathways
13.59 HRAS KIT KRAS LYN PIK3CA SRC
5
Show member pathways
13.51 BRAF HRAS KIT KRAS LYN PIK3CA
6
Show member pathways
13.44 HRAS KRAS LYN PIK3CA SRC TP53
7
Show member pathways
13.36 BRAF FES HRAS JUN KRAS LYN
8
Show member pathways
13.21 BRAF HRAS KIT KRAS LYN SRC
9
Show member pathways
13.2 HRAS JUN KRAS LYN PIK3CA RB1
10
Show member pathways
13.14 BRAF HRAS JUN KRAS SRC TP53
11
Show member pathways
13.13 HRAS KIT KRAS PIK3CA RB1 TP53
12
Show member pathways
13.11 HRAS JUN KRAS PIK3CA RB1 SRC
13
Show member pathways
13.08 CHEK2 HRAS JUN KRAS LYN SRC
14
Show member pathways
13.05 BRAF HRAS JUN KRAS PIK3CA SRC
15
Show member pathways
13.05 BRAF HRAS JUN KRAS PIK3CA RB1
16
Show member pathways
13.04 BRAF HRAS JUN KRAS LYN PIK3CA
17
Show member pathways
13.04 BRAF HRAS JUN KIT KRAS LYN
18
Show member pathways
13.01 BRAF HRAS JUN KRAS PIK3CA SRC
19 12.97 BRAF HRAS JUN KIT KRAS PIK3CA
20
Show member pathways
12.95 BRAF HRAS KRAS LYN PIK3CA SRC
21
Show member pathways
12.92 HRAS JUN KRAS PIK3CA TP53
22
Show member pathways
12.92 BRAF HRAS JUN KRAS SRC
23 12.92 BRAF HRAS JUN KIT KRAS TP53
24
Show member pathways
12.89 BRAF HRAS JUN KRAS PIK3CA
25
Show member pathways
12.89 BRAF HRAS KIT KRAS PIK3CA SRC
26
Show member pathways
12.87 BRAF HRAS JUN KRAS PIK3CA RB1
27
Show member pathways
12.86 HRAS KIT KRAS LYN PIK3CA SRC
28
Show member pathways
12.85 BRAF HRAS JUN KRAS SRC
29
Show member pathways
12.85 BRAF HRAS JUN KRAS PIK3CA SRC
30
Show member pathways
12.85 BRAF HRAS JUN KIT KRAS PIK3CA
31
Show member pathways
12.84 BRAF HRAS JUN KRAS RB1 TP53
32
Show member pathways
12.83 BRAF HRAS JUN KIT KRAS PIK3CA
33
Show member pathways
12.8 HRAS JUN KRAS PIK3CA SRC
34 12.77 BRAF HRAS KRAS PIK3CA SRC
35
Show member pathways
12.75 FES HRAS KRAS PIK3CA SRC TP53
36
Show member pathways
12.75 HRAS JUN KRAS LYN PIK3CA SRC
37
Show member pathways
12.74 HRAS LYN PIK3CA SRC YES1
38
Show member pathways
12.72 BRAF HRAS KRAS PIK3CA SRC
39
Show member pathways
12.66 BRAF HRAS JUN KRAS PIK3CA
40
Show member pathways
12.65 BRAF HRAS KRAS PIK3CA TP53
41
Show member pathways
12.63 HRAS JUN KRAS PIK3CA SRC
42
Show member pathways
12.6 CHEK2 HRAS JUN KRAS PIK3CA TP53
43
Show member pathways
12.59 HRAS JUN KRAS PIK3CA SRC
44
Show member pathways
12.58 BRAF HRAS KIT KRAS RB1
45
Show member pathways
12.58 BRAF HRAS JUN KRAS LYN SRC
46
Show member pathways
12.58 BRAF HRAS JUN KRAS PIK3CA SRC
47
Show member pathways
12.56 HRAS JUN KRAS PIK3CA SRC
48
Show member pathways
12.56 HRAS JUN KIT KRAS PIK3CA
49
Show member pathways
12.56 HRAS KRAS LYN PIK3CA SRC YES1
50
Show member pathways
12.54 HRAS KRAS LYN SRC

GO Terms for Sarcoma

Cellular components related to Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 postsynaptic specialization, intracellular component GO:0099091 9.13 LYN SRC YES1
2 extrinsic component of cytoplasmic side of plasma membrane GO:0031234 9.02 FES KRAS LYN SRC YES1

Biological processes related to Sarcoma according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 BRAF HRAS KIT KRAS SRC TP53
2 MAPK cascade GO:0000165 9.95 BRAF HRAS KIT KRAS
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.95 BRAF HRAS JUN KIT SRC
4 leukocyte migration GO:0050900 9.93 LYN PIK3CA SRC YES1
5 positive regulation of protein phosphorylation GO:0001934 9.92 CHEK2 HRAS KRAS LYN
6 phosphorylation GO:0016310 9.92 BRAF CHEK2 FES KIT LYN PIK3CA
7 Fc-gamma receptor signaling pathway involved in phagocytosis GO:0038096 9.88 LYN PIK3CA SRC YES1
8 protein phosphorylation GO:0006468 9.86 BRAF CHEK2 FES KIT LYN PIK3CA
9 liver development GO:0001889 9.84 JUN KRAS PIK3CA
10 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.84 KIT LYN SRC YES1
11 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 LYN SRC TP53 YES1
12 cellular response to drug GO:0035690 9.82 BRAF CHEK2 TP53
13 ephrin receptor signaling pathway GO:0048013 9.8 HRAS LYN SRC YES1
14 visual learning GO:0008542 9.78 BRAF KIT KRAS
15 negative regulation of neuron apoptotic process GO:0043524 9.77 BRAF HRAS JUN KRAS PIK3CA
16 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.76 HRAS KRAS LYN SRC
17 peptidyl-tyrosine autophosphorylation GO:0038083 9.75 LYN SRC YES1
18 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.74 KIT LYN SRC
19 cellular response to gamma radiation GO:0071480 9.73 CHEK2 HRAS TP53
20 positive regulation of MAP kinase activity GO:0043406 9.73 HRAS KIT KRAS SRC
21 T cell costimulation GO:0031295 9.71 LYN PIK3CA SRC YES1
22 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.67 CHEK2 TP53
23 positive regulation of phospholipase C activity GO:0010863 9.67 HRAS KIT
24 replicative senescence GO:0090399 9.67 CHEK2 TP53
25 negative regulation of telomerase activity GO:0051974 9.66 SRC TP53
26 regulation of vascular permeability GO:0043114 9.65 SRC YES1
27 regulation of mast cell degranulation GO:0043304 9.65 FES LYN
28 response to isolation stress GO:0035900 9.63 HRAS KRAS
29 peptidyl-tyrosine phosphorylation GO:0018108 9.63 BRAF FES KIT LYN SRC YES1
30 myeloid progenitor cell differentiation GO:0002318 9.61 BRAF KIT
31 response to mineralocorticoid GO:0051385 9.59 KRAS SRC
32 protein autophosphorylation GO:0046777 9.43 CHEK2 FES KIT LYN SRC YES1
33 Ras protein signal transduction GO:0007265 9.02 HRAS JUN KRAS RB1 TP53
34 regulation of transcription, DNA-templated GO:0006355 10.22 CHEK2 EWSR1 FLI1 JUN RB1 SSX1
35 positive regulation of transcription, DNA-templated GO:0045893 10.08 CHEK2 FLI1 JUN RB1 SRC TP53
36 cell differentiation GO:0030154 10.08 BRAF FLI1 KIT LYN RB1 SRC
37 negative regulation of cell proliferation GO:0008285 10.04 HRAS JUN LYN RB1 TP53

Molecular functions related to Sarcoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.88 BRAF CHEK2 HRAS KIT KRAS
2 protein kinase activity GO:0004672 9.87 BRAF CHEK2 FES KIT LYN SRC
3 enzyme binding GO:0019899 9.85 JUN LYN RB1 SRC TP53 YES1
4 ubiquitin protein ligase binding GO:0031625 9.73 CHEK2 JUN LYN RB1 SRC TP53
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.67 KIT PIK3CA SRC
6 phosphoprotein binding GO:0051219 9.63 LYN RB1 SRC
7 kinase activity GO:0016301 9.56 BRAF CHEK2 FES KIT LYN PIK3CA
8 non-membrane spanning protein tyrosine kinase activity GO:0004715 9.46 FES LYN SRC YES1
9 protein tyrosine kinase activity GO:0004713 9.1 BRAF FES KIT LYN SRC YES1
10 protein binding GO:0005515 10.39 BRAF CHEK2 EWSR1 FES FLI1 HOTAIR
11 transferase activity GO:0016740 10.11 BRAF CHEK2 FES KIT LYN PIK3CA
12 ATP binding GO:0005524 10.06 BRAF CHEK2 FES KIT LYN PIK3CA

Sources for Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....